MX2019014298A - Formas de dosificacion liquida para tratar el cancer. - Google Patents
Formas de dosificacion liquida para tratar el cancer.Info
- Publication number
- MX2019014298A MX2019014298A MX2019014298A MX2019014298A MX2019014298A MX 2019014298 A MX2019014298 A MX 2019014298A MX 2019014298 A MX2019014298 A MX 2019014298A MX 2019014298 A MX2019014298 A MX 2019014298A MX 2019014298 A MX2019014298 A MX 2019014298A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage forms
- liquid dosage
- treat cancer
- cabozantinib
- patients
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000008297 liquid dosage form Substances 0.000 title 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 abstract 1
- 229960001292 cabozantinib Drugs 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 208000037843 metastatic solid tumor Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010044412 transitional cell carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517736P | 2017-06-09 | 2017-06-09 | |
| US201762520768P | 2017-06-16 | 2017-06-16 | |
| PCT/US2018/036703 WO2018227119A1 (en) | 2017-06-09 | 2018-06-08 | Liquid dosage forms to treat cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014298A true MX2019014298A (es) | 2020-02-03 |
Family
ID=62779087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014298A MX2019014298A (es) | 2017-06-09 | 2018-06-08 | Formas de dosificacion liquida para tratar el cancer. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11504362B2 (https=) |
| EP (1) | EP3634413A1 (https=) |
| JP (1) | JP7249962B2 (https=) |
| KR (1) | KR102647794B1 (https=) |
| CN (1) | CN110678180A (https=) |
| AU (1) | AU2018279834B2 (https=) |
| CA (1) | CA3065560A1 (https=) |
| MX (1) | MX2019014298A (https=) |
| UA (1) | UA126402C2 (https=) |
| WO (1) | WO2018227119A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013020362A2 (pt) * | 2011-02-10 | 2018-05-29 | Exelixis Inc | processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem |
| AU2018279834B2 (en) | 2017-06-09 | 2024-05-23 | Exelixis, Inc. | Liquid dosage forms to treat cancer |
| CN117402114A (zh) | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| TWI831259B (zh) | 2018-06-15 | 2024-02-01 | 漢達生技醫藥股份有限公司 | 包含達沙替尼十二烷基硫酸鹽組合物的膠囊 |
| WO2024163400A1 (en) | 2023-01-31 | 2024-08-08 | Handa Oncology, Llc | Improved cabozantinib compositions and methods of use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136846A (en) * | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| US7989490B2 (en) * | 2004-06-02 | 2011-08-02 | Cordis Corporation | Injectable formulations of taxanes for cad treatment |
| US20080200515A1 (en) | 2006-12-29 | 2008-08-21 | Tap Pharmaceutical Products Inc. | Solid state forms of enantiopure ilaprazole |
| NZ779754A (en) | 2009-01-16 | 2023-04-28 | Exelixis Inc | Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| US20120070368A1 (en) * | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| PE20131137A1 (es) * | 2010-10-29 | 2013-10-03 | Troikaa Pharmaceuticals Ltd | Composiciones nasales de vitamina b12 |
| MX2013012695A (es) | 2011-05-02 | 2014-03-27 | Exelixis Inc | Metodo para el tratamiento del cancer y el dolor por cancer de hueso. |
| EP2758057B1 (en) * | 2011-09-22 | 2017-05-31 | Exelixis, Inc. | Method for treating osteoporosis |
| ITRM20120331A1 (it) | 2012-07-12 | 2014-01-13 | Guidotti & C Spa Labor | Composizioni pediatriche orali liquide contenenti nepadutant. |
| JP6464084B2 (ja) | 2012-07-27 | 2019-02-06 | イズミ テクノロジー，エルエルシー | 排出阻害剤およびこれを用いる治療法 |
| BR112016018450A2 (pt) | 2014-02-14 | 2018-09-18 | Exelixis Inc | formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso |
| UA121655C2 (uk) | 2014-04-25 | 2020-07-10 | Екселіксіс, Інк. | Спосіб лікування аденокарциноми легень |
| EP3174854B1 (en) * | 2014-07-31 | 2022-08-24 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
| AU2018279834B2 (en) | 2017-06-09 | 2024-05-23 | Exelixis, Inc. | Liquid dosage forms to treat cancer |
-
2018
- 2018-06-08 AU AU2018279834A patent/AU2018279834B2/en active Active
- 2018-06-08 WO PCT/US2018/036703 patent/WO2018227119A1/en not_active Ceased
- 2018-06-08 EP EP18735102.8A patent/EP3634413A1/en not_active Withdrawn
- 2018-06-08 MX MX2019014298A patent/MX2019014298A/es unknown
- 2018-06-08 CN CN201880035207.9A patent/CN110678180A/zh active Pending
- 2018-06-08 US US16/620,379 patent/US11504362B2/en active Active
- 2018-06-08 KR KR1020207000409A patent/KR102647794B1/ko active Active
- 2018-06-08 UA UAA201912200A patent/UA126402C2/uk unknown
- 2018-06-08 CA CA3065560A patent/CA3065560A1/en active Pending
- 2018-06-08 JP JP2019567635A patent/JP7249962B2/ja active Active
-
2022
- 2022-10-28 US US17/975,765 patent/US12016854B2/en active Active
-
2024
- 2024-05-10 US US18/661,030 patent/US20240307367A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN110678180A (zh) | 2020-01-10 |
| US20200268737A1 (en) | 2020-08-27 |
| US12016854B2 (en) | 2024-06-25 |
| US20230301978A1 (en) | 2023-09-28 |
| US20240307367A1 (en) | 2024-09-19 |
| JP2020523317A (ja) | 2020-08-06 |
| AU2018279834B2 (en) | 2024-05-23 |
| UA126402C2 (uk) | 2022-09-28 |
| US11504362B2 (en) | 2022-11-22 |
| BR112019025110A2 (pt) | 2020-09-01 |
| KR102647794B1 (ko) | 2024-03-15 |
| JP7249962B2 (ja) | 2023-03-31 |
| EP3634413A1 (en) | 2020-04-15 |
| WO2018227119A1 (en) | 2018-12-13 |
| KR20200014903A (ko) | 2020-02-11 |
| AU2018279834A1 (en) | 2020-01-16 |
| CA3065560A1 (en) | 2018-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201904652B (en) | Combinations of cabozantinib and atezolizumab to treat cancer | |
| MX2019014298A (es) | Formas de dosificacion liquida para tratar el cancer. | |
| PH12017550063A1 (en) | Combination therapies for treating cancers | |
| PL3431105T3 (pl) | Kompozycja lecznicza do leczenia raka | |
| IL259119B (en) | Biparotropic peptides, a pharmaceutical preparation containing them and drugs for the treatment of cancer containing them | |
| PH12016501171A1 (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
| MX2016007282A (es) | Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico. | |
| SI3334431T1 (sl) | 5-bromo-2,6-di-(1h-pirazol-l-il)pyrimidin-4-amin za uporabo v zdravljenju raka | |
| MY187540A (en) | Compounds active towards bromodomains | |
| EP4691562A3 (en) | Anti-pd-l1 combinations for treating tumors | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| PH12015502112A1 (en) | Cancer treatment using antibodies that bind cell surface grp78 | |
| IN2014MU00303A (https=) | ||
| HK1253098A1 (zh) | 用於治疗癌症的mdm2抑制剂的给药方案 | |
| EP3548088A4 (en) | THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITÉCAN (IMMU-132) | |
| MX2019015527A (es) | Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino. | |
| MX2019015676A (es) | Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. | |
| NZ707636A (en) | Ingenol-derived compounds that can be used for treating cancer | |
| EP4541423A3 (en) | Dosing regimen of avelumab for the treatment of cancer | |
| EA201700286A1 (ru) | Макромолекулярные комплексы переходного металла для лечения рака и способ их получения | |
| MX2018009274A (es) | Cancer. | |
| BR112019025164A2 (pt) | Esquema de dosagem para tesetaxel e capecitabina | |
| EA201992830A1 (ru) | Жидкие лекарственные формы для лечения рака | |
| EA201991727A1 (ru) | Комбинации кабозантиниба и атезолизумаба для лечения рака | |
| NZ725303A (en) | Anti-tumor agent containing taxane compound, and anti-tumor effect enhancer |